Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

INFECTIOUS DISEASES SOCIETY OF AMERICA

Filed by ARENTFOX SCHIFF LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 19, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
a4c56884-be97-445b-8df8-9386738e77c5
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MED · Medical/Disease Research/Clinical Labs

Legislation related to anti-microbial resistence generally

BUD · Budget/Appropriations

Fiscal Year 2026 funding for Bio-Preparedness Workforce Pilot Program, programs dealing with antimicrobial resistance, and programs dealing with infectious diseases generally H. Con. Res 14, regarding funding for infectious diseases programs generally S. Con. Res 7, regarding funding for infectious diseases programs generally H.R. 1968 (Full-Year Continuing Appropriations and Extensions Act, 2025), regarding funding for Infectious diseases programs FY 2025 funding for infectious diseases programs generally Note: Elizabeth Horner, a lobbyist for the listed client, did not lobby, and did not make any communication to, appearance before, or lobbying contact with, the Senate, any Senator or any officer or employee of the Senate, on behalf of the listed client.

Literal federal measure citations: H. Con. Res 14, S. Con. Res 7, H.R. 1968

MMM · Medicare/Medicaid

Medicare reimbursement regarding evaluation and management services by infectious disease physicians, including 2026 Physician Fee Schedule

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.